<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Tryptophan Res</journal-id><journal-id journal-id-type="iso-abbrev">Int J Tryptophan Res</journal-id><journal-id journal-id-type="publisher-id">TRY</journal-id><journal-id journal-id-type="hwp">sptry</journal-id><journal-title-group><journal-title>International Journal of Tryptophan Research : IJTR</journal-title></journal-title-group><issn pub-type="epub">1178-6469</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31903023</article-id><article-id pub-id-type="pmc">6933542</article-id><article-id pub-id-type="doi">10.1177/1178646919891736</article-id><article-id pub-id-type="publisher-id">10.1177_1178646919891736</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Induction of tryptophan 2,3-dioxygenase expression in human monocytic
leukemia/lymphoma cell lines THP-1 and U937</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hoffmann</surname><given-names>Delia</given-names></name><xref ref-type="aff" rid="aff1-1178646919891736">1</xref><xref ref-type="aff" rid="aff2-1178646919891736">2</xref></contrib><contrib contrib-type="author"><name><surname>Pilotte</surname><given-names>Luc</given-names></name><xref ref-type="aff" rid="aff1-1178646919891736">1</xref><xref ref-type="aff" rid="aff2-1178646919891736">2</xref></contrib><contrib contrib-type="author"><name><surname>Stroobant</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="aff1-1178646919891736">1</xref><xref ref-type="aff" rid="aff2-1178646919891736">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4995-3270</contrib-id><name><surname>Van den Eynde</surname><given-names>Benoit J</given-names></name><xref ref-type="aff" rid="aff1-1178646919891736">1</xref><xref ref-type="aff" rid="aff2-1178646919891736">2</xref><xref ref-type="aff" rid="aff3-1178646919891736">3</xref><xref ref-type="corresp" rid="corresp1-1178646919891736"/></contrib></contrib-group><aff id="aff1-1178646919891736"><label>1</label>Ludwig Institute for Cancer Research,
Brussels, Belgium</aff><aff id="aff2-1178646919891736"><label>2</label>de Duve Institute, UCLouvain, Brussels,
Belgium</aff><aff id="aff3-1178646919891736"><label>3</label>Walloon Excellence in Life Sciences and
Biotechnology, Brussels, Belgium</aff><author-notes><corresp id="corresp1-1178646919891736">Beno&#x000ee;t Van den Eynde, Ludwig Institute for
Cancer Research, Avenue Hippocrate, 75 B1.74.03, Brussels B-1200, Belgium.
Email: <email>benoit.vandeneynde@bru.licr.org</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>12</volume><elocation-id>1178646919891736</elocation-id><history><date date-type="received"><day>12</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>1</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>Tumor-associated macrophages are immune cells with diverse functions in tumor
development. Among other functions, they downregulate immune-mediated tumor
rejection by depriving lymphocytes of nutrients. The essential amino acid
tryptophan is metabolized by the enzymes indoleamine 2,3-dioxygenase 1 and
tryptophan 2,3-dioxygenase (TDO). Indoleamine 2,3-dioxygenase 1 is expressed in
a large number of human tumors, and inhibitors are in development to improve
immunotherapy. Tryptophan 2,3-dioxygenase was also found in human tumors and
preclinical working models confirmed its immunosuppressive power. We explored a
potential expression of TDO by macrophages. This enzyme could be induced in two
human cell lines, THP-1 and U937, by incubation with phorbol myristate acetate,
lipopolysaccharide, and interferon gamma. Phorbol-myristate-acetate-mediated
induction was inhibited by rottlerin, a protein kinase C inhibitor. In contrast
to these monocytic cell lines, other cell lines or fresh human monocytes
isolated from peripheral blood mononuclear cells and differentiated into
proinflammatory or anti-inflammatory macrophages could not be induced to express
TDO. Our results suggest that TDO might play an immunosuppressive role in human
monocytic leukemias but not in untransformed macrophages.</p></abstract><kwd-group><kwd>Tryptophan 2,3-dioxygenase</kwd><kwd>PMA</kwd><kwd>PKC</kwd><kwd>monocyte</kwd><kwd>IFN-gamma</kwd><kwd>LPS</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2019</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-1178646919891736"><title>Introduction</title><p>Macrophages represent an important cell type implicated in all stages of tumor
development. During tumor initiation, macrophages create a proinflammatory
environment which causes tissue and DNA damage. In established tumors, macrophages
stimulate tissue remodeling, angiogenesis, inhibit immune-mediated tumor rejection,
and finally, favor metastases formation.<sup><xref rid="bibr1-1178646919891736" ref-type="bibr">1</xref><xref rid="bibr2-1178646919891736" ref-type="bibr"/>-<xref rid="bibr3-1178646919891736" ref-type="bibr">3</xref></sup></p><p>One particular immunosuppressive mechanism of macrophages is nutrient starvation.
Immunosuppressive macrophages express the enzyme arginase 1 which impairs T-cell
function and proliferation by decreasing arginine and increasing urea concentrations
in the tumor microenvironment.<sup><xref rid="bibr4-1178646919891736" ref-type="bibr">4</xref>,<xref rid="bibr5-1178646919891736" ref-type="bibr">5</xref></sup> Another example of nutrient
starvation is the expression of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1),
catalyzing the first and rate-limiting step of tryptophan degradation. Indoleamine
2,3-dioxygenase 1 impacts lymphocyte proliferation and activity in a 2-fold way by
nutrient deprivation and metabolite production and favors their differentiation to a
regulatory T-cell phenotype.<sup><xref rid="bibr6-1178646919891736" ref-type="bibr">6</xref><xref rid="bibr7-1178646919891736" ref-type="bibr"/><xref rid="bibr8-1178646919891736" ref-type="bibr"/>-<xref rid="bibr9-1178646919891736" ref-type="bibr">9</xref></sup> In normal human tissues, IDO1
expression is mainly restricted to the placenta, where it is believed to favor
feto-maternal tolerance<sup><xref rid="bibr10-1178646919891736" ref-type="bibr">10</xref></sup> and to mature dendritic cells. In addition, IDO1 is induced by IFN&#x003b3; during
inflammation<sup><xref rid="bibr11-1178646919891736" ref-type="bibr">11</xref>,<xref rid="bibr12-1178646919891736" ref-type="bibr">12</xref></sup> as a mechanism of retro-control of immune responses. Many human
cancers also express IDO1 in order to escape immune-mediated tumor
rejection.<sup><xref rid="bibr13-1178646919891736" ref-type="bibr">13</xref>,<xref rid="bibr14-1178646919891736" ref-type="bibr">14</xref></sup> Indoleamine 2,3-dioxygenase 1 expression is induced by IFN&#x003b3; in
tumor cells and stromal cells of inflamed tumors, as an adaptive resistance mechanism.<sup><xref rid="bibr15-1178646919891736" ref-type="bibr">15</xref></sup> Tumor cells may also express IDO1 in a constitutive manner, thereby mediating
intrinsic resistance. Constitutive IDO1 expression is triggered in tumor cells by
constitutively active COX2, producing prostaglandin which acts in an autocrine manner.<sup><xref rid="bibr16-1178646919891736" ref-type="bibr">16</xref></sup> Those discoveries led to the synthesis of several small molecule inhibitors
which are currently in clinical development.<sup><xref rid="bibr17-1178646919891736" ref-type="bibr">17</xref></sup></p><p>The enzyme tryptophan 2,3-dioxygenase (protein TDO encoded by gene
<italic>TDO2</italic>), exerting the same enzymatic activity as IDO1, is
expressed in the liver to regulate systemic tryptophan concentrations, in the murine
placenta where it might contribute to feto-maternal tolerance and in tumors where it
downregulates immune-mediated tumor rejection<sup><xref rid="bibr8-1178646919891736" ref-type="bibr">8</xref>,<xref rid="bibr18-1178646919891736" ref-type="bibr">18</xref><xref rid="bibr19-1178646919891736" ref-type="bibr"/><xref rid="bibr20-1178646919891736" ref-type="bibr"/>-<xref rid="bibr21-1178646919891736" ref-type="bibr">21</xref></sup>. Enzymatically active TDO is
also constitutively expressed by several human tumor cell lines like glioblastoma,
colorectal, head and neck, and lung and gall-bladder carcinoma cell lines.<sup><xref rid="bibr18-1178646919891736" ref-type="bibr">18</xref></sup> In addition, microarray data showed that <italic>TDO2</italic> mRNA was
upregulated in the tumor-derived monocytic cell line THP-1 by differentiating the
cells into a macrophage-like phenotype using phorbol 12-myristate 13-acetate (PMA).<sup><xref rid="bibr22-1178646919891736" ref-type="bibr">22</xref></sup> This observation opens up the possibility that TDO might be induced in
macrophages in tumors or other pathologies. In this report, we characterize the
expression and enzymatic activity of TDO induced by PMA in two monocytic
leukemia/lymphoma cell lines, THP-1 and U937, by lipopolysaccharide (LPS) alone in
THP-1 cells and by a combination of LPS and interferon gamma (IFN&#x003b3;) in U937 cells.
We also highlight the lack of TDO induction in human monocytes freshly isolated from
peripheral blood mononuclear cells (PBMCs).</p></sec><sec sec-type="materials|methods" id="section2-1178646919891736"><title>Materials and Methods</title><sec id="section3-1178646919891736"><title>Compounds</title><p>PMA was purchased from Sigma (#P8139). Recombinant human IFN&#x003b3; was purchased from
BD Biosciences (#554617). Lipopolysaccharide <italic>Escherichia coli</italic>
O111:B4 was purchased from Sigma (#L2630). Rottlerin was purchased from Sigma
(#R5648). Recombinant human granulocyte-macrophage colony-stimulating factor
(GM-CSF) was purchased from Sanofi (Leukine sargramostim). Recombinant human
macrophage colony-stimulating factor 1 (M-CSF) was purchased from GenScript
(#Z02001). Recombinant human interleukin-4 (IL-4) was produced at the Ludwig
Cancer Research (Brussels, Belgium). Recombinant human IL-10 was purchased from
R&#x00026;D (#1064-IL). Ribomunyl was purchased from Pierre Fabre (France).
Prostaglandin E2 (PGE2) was purchased from Sigma. Recombinant human tumor
necrosis factor alpha (TNF&#x003b1;) was purchased from PeproTech (#300-01A).
Recombinant human transforming growth factor beta (TGF&#x003b2;) was purchased from
R&#x00026;D (#240-B).</p></sec><sec id="section4-1178646919891736"><title>Cancer cell lines and in vitro induction of TDO</title><p>THP-1 and U937 cell lines were purchased from ATCC. Cells were plated in complete
culture medium: 0.016&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells in 96-well plates for the viability
assay, 0.2&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells in 12-well plates for real-time quantitative
polymerase chain reaction (RT-qPCR; except from <xref ref-type="fig" rid="fig2-1178646919891736">Figure 2</xref>: 0.2-1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells)
and 1.2&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells in 60-mm dishes for western blot. PMA
(0.5-25&#x02009;ng/mL), IFN&#x003b3; (50&#x02009;ng/mL), LPS (1&#x02009;&#x000b5;g/mL), and rottlerin (5&#x02009;nM) were added
and cells were incubated for 48&#x02009;hours at 37&#x000b0;C, 8% CO<sub>2</sub>.</p></sec><sec id="section5-1178646919891736"><title>Isolation of human monocytes and in vitro induction of TDO</title><p>Peripheral blood mononuclear cells were isolated from human blood by lymphoprep
centrifugation. Monocytes were enriched by negative selection using EasySep
Human Monocyte Enrichment Kit without CD16 Depletion (Stemcell, #19058). Five
million cells were plated in complete culture medium. PMA (1-20&#x02009;ng/mL), IFN&#x003b3;
(5&#x02009;ng/mL), LPS (100&#x02009;ng/mL), GM-CSF (100&#x02009;ng/mL), M-CSF (100&#x02009;ng/mL), IL-4
(20&#x02009;ng/mL), IL-10 (10&#x02009;ng/mL), ribomunyl (1&#x02009;&#x000b5;g/mL), PGE2 (500&#x02009;ng/mL), TNF&#x003b1;
(10&#x02009;ng/mL), and TGF&#x003b2; (4&#x02009;ng/mL) were added, and cells were incubated for
indicated durations at 37&#x000b0;C, 8% CO<sub>2</sub>.</p></sec><sec id="section6-1178646919891736"><title>Western blot</title><p>The cells were lysed in Pierce Ripa buffer (Thermo Scientific, #89901) with Halt
Protease and Phosphatase inhibitor Cocktail (Thermo Scientific, #78446); genomic
DNA was then lysed by 15&#x02009;seconds of sonication; the lysates were shaken for
30&#x02009;minutes at 4&#x000b0;C, centrifuged for 10&#x02009;minutes at 20&#x02009;000<italic>g</italic>; and
the protein concentration of the supernatant was determined by Pierce Protein
BCA Assay Kit (Thermo Scientific, #23225). The proteins were heated at 95&#x000b0;C for
5&#x02009;minutes with a homemade loading buffer 6x (SDS 12%w/v, bromophenol blue
0.06%w/v, glycerol 47%, Tris 0,5 M pH 6.8, DTT 9.3% w/v). Twenty micrograms of
proteins were loaded on NuPAGE Bis Tris 4% to 12% gels (Invitrogen #WG1402BOX)
and separated by gel electrophoresis using MOPS running buffer (NuPAGE,
#NP0001). Dry transfer was performed by iBlot (Thermo Scientific) using iBlot
Gel Transfer Stacks, nitrocellulose, regular size (Thermo Scientific, #IB301001)
and a transfer program of 7&#x02009;minutes (1&#x02009;minute at 20&#x02009;V, 4&#x02009;minutes at 23&#x02009;V, and
2&#x02009;minutes at 25&#x02009;V). After blocking in phosphate-buffered saline (PBS) with 5%
dry milk and 0.1% Tween 20 for 1&#x02009;hour at room temperature, the membranes were
incubated with the primary antibodies diluted in blocking buffer: mouse anti-TDO
clone III at 1&#x02009;&#x000b5;g/mL (validated previously),<sup><xref rid="bibr23-1178646919891736" ref-type="bibr">23</xref></sup> mouse anti-Vinculin clone hVIN-1 at 1:10&#x02009;000 (Sigma, #V9131) for 2 hours
at room temperature or homemade mouse anti-IDO1 clone 4.16H1 at 2&#x02009;&#x000b5;g/mL<sup><xref rid="bibr14-1178646919891736" ref-type="bibr">14</xref></sup> overnight at 4&#x000b0;C. After washing in PBS with 0.1% Tween 20, the membranes
were incubated with horseradish peroxidase (HRP)-linked goat antimouse IgG
antibody (BioLegend, #405306) at 1:2500 in blocking buffer for 1&#x02009;hour at room
temperature and washed again with PBS-Tween 20. The HRP was revealed using
SuperSignal West Pico (Thermo Scientific, #1859674) and detected with Fusion
Solo S (Vilber Lourmat). The intensity of the bands was quantified using Bio-1D
software.</p></sec><sec id="section7-1178646919891736"><title>Quantitative RT-PCR</title><p>RNA was extracted with NucleoSpin RNA (Macherey Nagel, #740955) according to the
manufacturer&#x02019;s instructions. The RNA was quantified with a NanoDrop 2000c
spectrophotometer (Thermo Scientific) and a defined amount of RNA was then
retro-transcribed by the RevertAid RT Kit (Thermo Scientific, #K1691) according
to the manufacturer&#x02019;s instructions. Quantitative polymerase chain reaction was
performed with Takyon ROX Probe 2X MasterMix dTTP blue (Eurogentec,
#UF-RPMT-B0701) in a StepOnePlus thermal cycler (Applied Biosystems) using the
following program for <italic>TDO2</italic> and <italic>IDO1</italic>: 3&#x02009;minutes
at 95&#x000b0;C, then 40 cycles of 10&#x02009;seconds at 95&#x000b0;C, and 1&#x02009;minute at 60&#x000b0;C; for
<italic>EF1</italic>: 3&#x02009;minutes at 95&#x000b0;C, then 40 cycles of 3&#x02009;seconds at
95&#x000b0;C, and 30&#x02009;seconds at 60&#x000b0;C. The following primers were used for
<italic>TDO2</italic>: CATGGCTGGAAAGAACTC (forward), CTGAAGTGCTCTGTATGAC
(reverse), TTTAGAGCCACATGGATTTAACTTCTGGG (probe); for <italic>IDO1</italic>:
GGTCATGGAGATGTCCGTAA (forward), ACCAATAGAGAGACCAGGAAGAA (reverse),
CTGTTCCTTACTGCCAACTCTCCAAGAAACTG (probe); for <italic>EF1</italic>:
GCTTCACTGCTCAGGTGAT (forward), GCCGTGTGGCAATCCAAT (reverse),
AAATAAGCGCCGGCTATGCCCCTG (probe). The probes were coupled to 5&#x02019; FAM and 3&#x02019;
TAMRA. Standard curves were added for each gene.</p></sec><sec id="section8-1178646919891736"><title>Tryptophan and kynurenine quantification</title><p>The cell culture supernatants were harvested and analyzed by high-performance
liquid chromatography (HPLC) as previously described.<sup><xref rid="bibr18-1178646919891736" ref-type="bibr">18</xref></sup></p></sec><sec id="section9-1178646919891736"><title>Viability test</title><p>Nineteen microliters of MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
inner salt) and 1&#x02009;&#x000b5;L of phenazine methosulfate (PMS) were added to the cells
(100 &#x000b5;L) which were then incubated for 3&#x02009;hours and 30&#x02009;minutes at 37&#x000b0;C. The
absorbance was measured with a GloMax spectrophotometer (Promega) at 490 nm with
reference at 600 nm.</p></sec></sec><sec sec-type="results" id="section10-1178646919891736"><title>Results</title><sec id="section11-1178646919891736"><title>TDO expression is induced by PMA in human monocytic cell lines</title><p>To confirm that TDO is induced in the monocytic cell line THP-1 by PMA-mediated differentiation,<sup><xref rid="bibr22-1178646919891736" ref-type="bibr">22</xref></sup> we treated two monocytic leukemia/lymphoma cell lines, THP-1 and U937,
with increasing concentrations of PMA. As expected, both cell lines became
adherent upon treatment with PMA and increased the expression of CD11c, CD14,
TNF&#x003b1;, and <italic>IL-1&#x003b2;</italic> (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1178646919891736">Supplementary Figure 1</ext-link>).<sup><xref rid="bibr24-1178646919891736" ref-type="bibr">24</xref><xref rid="bibr25-1178646919891736" ref-type="bibr"/><xref rid="bibr26-1178646919891736" ref-type="bibr"/><xref rid="bibr27-1178646919891736" ref-type="bibr"/>-<xref rid="bibr28-1178646919891736" ref-type="bibr">28</xref></sup> We observed that
<italic>TDO2</italic> mRNA and metabolically active protein were induced in
a dose-dependent manner (<xref ref-type="fig" rid="fig1-1178646919891736">Figure
1A</xref> to <xref ref-type="fig" rid="fig1-1178646919891736">C</xref>). The
viability of THP-1 cells, analyzed by the colorimetric MTS-PMS assay, was not
affected, but U937 cells showed 50% of mortality upon differentiation with PMA
(<xref ref-type="fig" rid="fig1-1178646919891736">Figure 1D</xref>).
Concerned about this high mortality rate, we analyzed apoptosis by propidium
iodide (PI) and annexin V flow cytometry and obtained about 70% of
double-negative, living cells (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1178646919891736">Supplementary Figure 2A</ext-link>). This discrepancy might be explained by
reduced cell proliferation upon PMA treatment. The MTS-PMS assay measures the
activity of dehydrogenase enzymes in metabolically active cells. As
PMA-differentiated cells stop proliferating (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1178646919891736">Supplementary Figure 2B</ext-link>), the conversion rate of MTS is reduced
compared to untreated cells. We treated other cell lines, like the human
myeloblast cell line HL60, murine macrophage cell lines (J774, RAW 264.7, MF4/4)
and human hepatocarcinoma cell lines (Huh-7 and Hep-G2), with PMA, but they did
not induce TDO expression (data not shown).</p><fig id="fig1-1178646919891736" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Induction of TDO by PMA. THP-1 and U937 cells were treated for 2&#x02009;days
with PMA ranging from 0.5 to 25&#x02009;ng/mL and <italic>TDO2</italic> mRNA,
TDO protein, kynurenine production, and cell viability were analyzed in
parallel. (A) <italic>TDO2</italic> mRNA was quantified by RT-qPCR. The
graphs show the mean&#x02009;&#x000b1;&#x02009;SEM (reported to 25&#x02009;ng/mL PMA) of three
independent experiments. The mean value (<italic>TDO2</italic>
transcripts per 2000 <italic>EF1</italic> transcripts) of the reference
condition is indicated on top of the relevant bar. (B) 30&#x02009;minutes before
harvesting the cells, 300&#x02009;&#x000b5;M of tryptophan was added to the cell culture
to stabilize the TDO protein. Tryptophan 2,3-dioxygenase and vinculin
(loading control) were revealed by western blot and quantified. The
graphs show the mean&#x02009;&#x000b1;&#x02009;SEM (reported to 25&#x02009;ng/mL PMA) of three
independent experiments. (C) The metabolite kynurenine was quantified in
the supernatants by HPLC. The graphs show the mean&#x02009;&#x000b1;&#x02009;SEM (reported to
25&#x02009;ng/mL PMA) of three independent experiments. The mean value (&#x000b5;M) of
the reference condition is indicated on top of the relevant bar. (D)
Cell viability was measured by an MTS-PMS assay. The graphs show the
mean optical density&#x02009;&#x000b1;&#x02009;SEM (reported to the untreated condition) of
three independent experiments.</p><p>HPLC indicates high-performance liquid chromatography; mRNA, messenger
ribonucleic acid; MTS,
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
inner salt; PMA, phorbol 12-myristate 13-acetate; PMS, phenazine
methosulfate; RT-qPCR, real-time quantitative polymerase chain reaction;
SEM, standard error of mean; TDO, tryptophan 2,3-dioxygenase.</p></caption><graphic xlink:href="10.1177_1178646919891736-fig1"/></fig></sec><sec id="section12-1178646919891736"><title>Induction of TDO by PMA depends on cell density</title><p>It is known that the cell density during culture can change the impact of PMA on
the cell phenotype and cytokine expression of THP-1 cells.<sup><xref rid="bibr29-1178646919891736" ref-type="bibr">29</xref></sup> We confirmed that the induction of TDO also depends on cell density
because the induction of TDO decreased dramatically when the cell density of
THP-1 and U937 cells increased (<xref ref-type="fig" rid="fig2-1178646919891736">Figure 2</xref>).</p><fig id="fig2-1178646919891736" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Impact of the cell density on the induction of TDO. THP-1 and U937 cells
were plated in 12-well plates ranging from 0.2 to 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup>
cells per well and were treated for 2&#x02009;days with 1&#x02009;ng/mL of PMA.
<italic>TDO2</italic> mRNA and kynurenine production were analyzed
in parallel. (A) <italic>TDO2</italic> mRNA was quantified by RT-qPCR.
The graphs show the mean&#x02009;&#x000b1;&#x02009;SEM (reported to 0.2&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells)
of three independent experiments. The mean value (<italic>TDO2</italic>
transcripts per 2000 <italic>EF1</italic> transcripts) of the reference
condition is indicated on top of the relevant bar. (B) The metabolite
kynurenine was quantified in the supernatants by HPLC. The graphs show
the kynurenine concentration divided by the corresponding cell
number&#x02009;&#x000b1;&#x02009;SEM (reported to 0.2&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells) of three
independent experiments. The mean value of the reference condition is
indicated on top of the relevant bar.</p><p>HPLC indicates high-performance liquid chromatography; PMA, phorbol 12-
myristate 13-acetate; RT-qPCR, real-time quantitative polymerase chain
reaction; SEM, standard error of mean; TDO, tryptophan
2,3-dioxygenase.</p></caption><graphic xlink:href="10.1177_1178646919891736-fig2"/></fig></sec><sec id="section13-1178646919891736"><title>The induction of TDO by PMA is PKC-dependent</title><p>We next wondered which signaling pathway leads to the induction of TDO in those
monocytic cell lines. As the protein kinase C (PKC) is a known target of PMA, we
treated the cells with rottlerin, a PKC inhibitor which primarily inhibits PKC&#x003b4;.
When the cells were treated simultaneously with PMA and rottlerin, the induction
of TDO was efficiently inhibited (<xref ref-type="fig" rid="fig3-1178646919891736">Figure 3A</xref> to <xref ref-type="fig" rid="fig3-1178646919891736">C</xref>). Although the viability of THP-1 cells
was only mildly affected, the reduced expression of TDO in U937 could be biased
by a high percentage of cell death upon rottlerin treatment (<xref ref-type="fig" rid="fig3-1178646919891736">Figure 3D</xref>).</p><fig id="fig3-1178646919891736" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Inhibition of the PKC pathway. THP-1 and U937 cells were treated for
2&#x02009;days with 10&#x02009;ng/mL of PMA, 5&#x02009;nM of rottlerin or DMSO and
<italic>TDO2</italic> mRNA, TDO protein, kynurenine production, and
cell viability were analyzed in parallel. (A) <italic>TDO2</italic> mRNA
was quantified by RT-qPCR. The graphs show the mean&#x02009;&#x000b1;&#x02009;SEM (reported to
PMA&#x02009;+&#x02009;DMSO) of three independent experiments. The mean value
(<italic>TDO2</italic> transcripts per 2000 <italic>EF1</italic>
transcripts) of the reference condition is indicated on top of the
relevant bar. (B) 30&#x02009;minutes before harvesting the cells, 300&#x02009;&#x000b5;M of
tryptophan was added to the cell culture to stabilize the TDO protein,
and TDO and vinculin (loading control) were revealed by western blot and
quantified. The graphs show the mean&#x02009;&#x000b1;SEM (reported to PMA&#x02009;+&#x02009;DMSO) of
three independent experiments. (C) The metabolite kynurenine was
quantified in the supernatants by HPLC. The graphs show the mean&#x02009;&#x000b1;&#x02009;SEM
(reported to PMA&#x02009;+&#x02009;DMSO) of three independent experiments. The mean
value (&#x000b5;M) of the reference condition is indicated on top of the
relevant bar. (D) Cell viability was measured by an MTS-PMS assay. The
graphs show the mean optical density&#x02009;&#x000b1;&#x02009;SEM (reported to DMSO alone) of
three independent experiments.</p><p>DMSO indicates dimethylsulfoxide; HPLC, high-performance liquid
chromatography; MTS,
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
inner salt; PMA, phorbol 12-myristate 13-acetate; PMS, phenazine
methosulfate; RT-qPCR, real-time quantitative polymerase chain reaction;
SEM, standard error of mean; TDO, tryptophan 2,3-dioxygenase.</p></caption><graphic xlink:href="10.1177_1178646919891736-fig3"/></fig></sec><sec id="section14-1178646919891736"><title>TDO expression is induced by LPS and IFN&#x003b3;</title><p>Beside PMA, monocytic cell lines can be differentiated and stimulated by LPS and
IFN&#x003b3;. We observed that LPS induced TDO in THP-1 cells, whose expression was
further increased by IFN&#x003b3;, whereas IFN&#x003b3; alone had little impact on TDO
expression (<xref ref-type="fig" rid="fig4-1178646919891736">Figure 4A</xref> to
<xref ref-type="fig" rid="fig4-1178646919891736">C</xref>). U937 cells
needed the combined treatment of IFN&#x003b3; and LPS to strongly induce TDO, compared
to their small response to LPS alone. As IFN&#x003b3; and LPS also induced IDO1 (<xref ref-type="fig" rid="fig5-1178646919891736">Figure 5</xref>), kynurenine was
probably partially produced by IDO1 and not exclusively by TDO in these
conditions. THP-1 cells tolerated well the treatment with LPS and IFN&#x003b3;, whereas
the viability of U937 cells was reduced to 65% (<xref ref-type="fig" rid="fig4-1178646919891736">Figure 4D</xref>).</p><fig id="fig4-1178646919891736" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Induction of TDO by IFN&#x003b3; and LPS. THP-1 and U937 cells were treated for
2&#x02009;days with 50&#x02009;ng/mL of IFN&#x003b3; and/or 1 &#x000b5;g/mL of LPS.
<italic>TDO2</italic> mRNA, TDO protein, kynurenine production, and
cell viability were analyzed in parallel. (A) <italic>TDO2</italic> mRNA
was quantified by RT-qPCR. The graphs show the mean&#x02009;&#x000b1;&#x02009;SEM (reported to
IFN&#x003b3;&#x02009;+&#x02009;LPS) of three independent experiments. The mean value
(<italic>TDO2</italic> transcripts per 2000 <italic>EF1</italic>
transcripts) of the reference condition is indicated on top of the
relevant bar. (B) 30&#x02009;minutes before harvesting the cells, 300&#x02009;&#x000b5;M of
tryptophan was added to the cell culture to stabilize the TDO protein,
and TDO and vinculin (loading control) were revealed by western blot and
quantified. The graphs show the mean&#x02009;&#x000b1;&#x02009;SEM (reported to IFN&#x003b3;&#x02009;+&#x02009;LPS) of
three independent experiments. (C) The metabolite kynurenine was
quantified in the supernatants by HPLC. The graphs show the mean&#x02009;&#x000b1;&#x02009;SEM
(reported to IFN&#x003b3;&#x02009;+&#x02009;LPS) of three independent experiments. The mean
value (&#x000b5;M) of the reference condition is indicated on top of the
relevant bar. (D) Cell viability was measured by an MTS-PMS assay. The
graphs show the mean optical density&#x02009;&#x000b1;&#x02009;SEM (reported to the untreated
condition) of three independent experiments.</p><p>HPLC indicates high-performance liquid chromatography; LPS,
lipopolysaccharide; MTS,
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
inner salt; PMA, phorbol 12-myristate 13-acetate; PMS, phenazine
methosulfate; RT-qPCR, real-time quantitative polymerase chain reaction;
SEM, standard error of mean; TDO, tryptophan 2,3-dioxygenase.</p></caption><graphic xlink:href="10.1177_1178646919891736-fig4"/></fig><fig id="fig5-1178646919891736" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Induction of IDO1 by IFN&#x003b3; and LPS. THP-1 and U937 cells were treated for
2&#x02009;days with 50&#x02009;ng/mL of IFN&#x003b3; and/or 1 &#x000b5;g/mL of LPS.
<italic>IDO1</italic> mRNA and IDO1 protein were analyzed in
parallel. (A) <italic>IDO1</italic> mRNA was quantified by RT-qPCR. The
graphs show the mean&#x02009;&#x000b1;&#x02009;SEM (reported to IFN&#x003b3;&#x02009;+&#x02009;LPS) of three independent
experiments. The mean value (<italic>IDO1</italic> transcripts per 2000
<italic>EF1</italic> transcripts) of the reference condition is
indicated on top of the relevant bar. (B) 30&#x02009;minutes before harvesting
the cells, 300&#x02009;&#x000b5;M of tryptophan was added to the cell culture, and IDO1
and vinculin (loading control) were revealed by western blot.</p><p>LPS indicates lipopolysaccharide; MTS,
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
inner salt; RT-qPCR, real-time quantitative polymerase chain reaction;
SEM, standard error of mean; TDO, tryptophan 2,3-dioxygenase.</p></caption><graphic xlink:href="10.1177_1178646919891736-fig5"/></fig></sec><sec id="section15-1178646919891736"><title>Treatments with other substrates</title><p>It was previously reported that the expression of TDO increased in liver cells
upon dexamethasone treatment, a synthetic glucocorticoid,<sup><xref rid="bibr30-1178646919891736" ref-type="bibr">30</xref>,<xref rid="bibr31-1178646919891736" ref-type="bibr">31</xref></sup> as well as
in uterine stromal cells upon decidualization with progesterone and estrogen.<sup><xref rid="bibr32-1178646919891736" ref-type="bibr">32</xref></sup> We treated THP-1 and U937 cells with dexamethasone, progesterone, and
estrogen. None of those substrates induced TDO in these monocytic cell lines
(data not shown).</p></sec><sec id="section16-1178646919891736"><title>TDO is not expressed by normal monocytes and macrophages</title><p>We finally studied the induction of TDO in normal monocytes or macrophages. If
confirmed, this would support the hypothesis that TDO can represent an
immunosuppressive mechanism exerted by macrophage infiltration in tumors and
other pathologies. The differentiation of freshly isolated monocytes into a
macrophage-like phenotype and their subsequent exposure to proinflammatory or
anti-inflammatory cytokines and chemokines did not induce TDO expression (<xref rid="table1-1178646919891736" ref-type="table">Table 1</xref> and <ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1178646919891736">Supplementary Figure 3</ext-link>).</p><table-wrap id="table1-1178646919891736" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Differentiation of freshly isolated monocytes.</p></caption><alternatives><graphic xlink:href="10.1177_1178646919891736-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">2&#x02009;days</th></tr></thead><tbody><tr><td colspan="2" rowspan="1">PMA 0, 0.5, 1, 2.5, 5&#x02009;ng/mL</td></tr><tr><th align="left" colspan="2" rowspan="1">5&#x02009;days</th></tr><tr><td colspan="2" rowspan="1">GM-CSF</td></tr><tr><td colspan="2" rowspan="1">GM-CSF&#x02009;+&#x02009;IFN&#x003b3;&#x02009;+&#x02009;LPS</td></tr><tr><td colspan="2" rowspan="1">GM-CSF&#x02009;+&#x02009;IL-4</td></tr><tr><td colspan="2" rowspan="1">GM-CSF&#x02009;+&#x02009;IL-4&#x02009;+&#x02009;PGE2</td></tr><tr><td colspan="2" rowspan="1">M-CSF</td></tr><tr><td colspan="2" rowspan="1">M-CSF&#x02009;+&#x02009;IL-4</td></tr><tr><td colspan="2" rowspan="1">M-CSF&#x02009;+&#x02009;IL-10</td></tr><tr><td colspan="2" rowspan="1">M-CSF&#x02009;+&#x02009;ribomunyl&#x02009;+&#x02009;LPS</td></tr><tr><td colspan="2" rowspan="1">IL-10&#x02009;+&#x02009;IL-4</td></tr><tr><td colspan="2" rowspan="1">PMA 5, 20&#x02009;ng/mL</td></tr><tr><th align="left" rowspan="1" colspan="1">5&#x02009;days</th><th align="left" rowspan="1" colspan="1">Then 2&#x02009;days</th></tr><tr><td rowspan="1" colspan="1">GM-CSF</td><td rowspan="1" colspan="1">/</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IFN&#x003b3;&#x02009;+&#x02009;LPS</td></tr><tr><td rowspan="1" colspan="1">GM-CSF&#x02009;+&#x02009;IL4</td><td rowspan="1" colspan="1">/</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">LPS</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ribomunyl</td></tr><tr><td rowspan="1" colspan="1">M-CSF</td><td rowspan="1" colspan="1">/</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IL-4</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ribomunyl&#x02009;+&#x02009;LPS</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IL-10</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">TGF&#x003b2;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">TNF&#x003b1;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IFN&#x003b3;&#x02009;+&#x02009;LPS</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1178646919891736"><p>The table lists all tested differentiation protocols and treatments
of freshly isolated human monocytes. Cells were isolated from
peripheral blood mononuclear cells and treated with either one
single dose of cytokines for 2 or 5&#x02009;days or differentiated for
5&#x02009;days and subsequently treated with cytokines for 2 other days. The
corresponding <italic>TDO2</italic> and <italic>IDO1</italic>
RT-qPCR results and kynurenine quantifications are shown in
<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1178646919891736">Supplementary Figure 3</ext-link>.</p></fn><fn id="table-fn2-1178646919891736"><p>Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating
factor; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide;
M-CSF, macrophage colony-stimulating factor; PMA, phorbol
12-myristate 13-acetate; TGF, transforming growth factor; TNF, tumor
necrosis factor.</p></fn></table-wrap-foot></table-wrap><p>Taken together, we found that TDO expression can be induced in monocytic cell
lines by PMA, LPS, and IFN&#x003b3;, but freshly isolated monocytes and other cell lines
failed to induce TDO.</p></sec></sec><sec sec-type="discussion" id="section17-1178646919891736"><title>Discussion</title><p>We found that TDO can be induced in THP-1 and U937 monocytic leukemia/lymphoma cell
lines upon differentiation with PMA or a combination of LPS and IFN&#x003b3;. The level of
protein TDO and its mRNA mostly correlated well, except for THP-1 cells treated with
the combination of LPS and IFN&#x003b3;. In this condition, the mRNA was comparable to LPS
treatment alone, but the protein level was lower in the presence of IFN&#x003b3; (<xref ref-type="fig" rid="fig4-1178646919891736">Figure 4A</xref> and <xref ref-type="fig" rid="fig4-1178646919891736">B</xref>). This might be explained by
the complete degradation of tryptophan by IDO1 (data not shown), which is massively
induced when combining LPS and IFN&#x003b3; (<xref ref-type="fig" rid="fig5-1178646919891736">Figure 5</xref>). It was recently shown that the
protein TDO is degraded in a proteasome-dependent manner in the absence of its
substrate tryptophan, although the mRNA remains unaffected (Klaessens et al., in preparation).<sup><xref rid="bibr33-1178646919891736" ref-type="bibr">33</xref></sup> Indoleamine 2,3-dioxygenase 1 was induced to a lesser extent in U937 cells
(<xref ref-type="fig" rid="fig5-1178646919891736">Figure 5</xref>). Tryptophan
was not completely degraded (data not shown) and indeed, TDO protein and mRNA
correlated well.</p><p>Tryptophan 2,3-dioxygenase expression and kynurenine production also correlated well,
except for THP-1 cells treated with PMA (<xref ref-type="fig" rid="fig1-1178646919891736">Figure 1A</xref> to <xref ref-type="fig" rid="fig1-1178646919891736">C</xref>). Surprisingly, kynurenine concentrations
decreased at PMA concentrations higher than 5&#x02009;ng/mL (<xref ref-type="fig" rid="fig1-1178646919891736">Figure 1C</xref>). We think that high PMA
concentrations might induce downstream enzymes leading to the degradation of
kynurenine.</p><p>We observed that TDO is probably induced by a PKC-mediated pathway (<xref ref-type="fig" rid="fig3-1178646919891736">Figure 3</xref> for PMA and data not
shown for LPS and IFN&#x003b3;), but we ignore the exact mechanism below PKC. Tryptophan
2,3-dioxygenase could be directly induced by this pathway or indirectly by the
induction of new cytokines. For example, the differentiation of the cells leads to
an increased expression and secretion of cytokines, like IL-1&#x003b2; and TNF&#x003b1; (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1178646919891736">Supplementary Figure 1</ext-link>),<sup><xref rid="bibr34-1178646919891736" ref-type="bibr">34</xref>,<xref rid="bibr35-1178646919891736" ref-type="bibr">35</xref></sup> which could induce TDO in an
autocrine manner. Interestingly, D&#x02019;Amato and co-workers found that triple-negative
breast cancer (TNBC) cells induce TDO when losing attachment to the cell culture support.<sup><xref rid="bibr36-1178646919891736" ref-type="bibr">36</xref></sup> These observations contrast with our results because nonadhering THP-1 and
U937 cells start attaching to the cell culture support when differentiated to a
macrophage-like phenotype with PMA or treated with LPS. On the contrary, we might
confirm their results showing that TDO is induced by NF&#x003ba;B signaling<sup><xref rid="bibr36-1178646919891736" ref-type="bibr">36</xref></sup> because PMA,<sup><xref rid="bibr37-1178646919891736" ref-type="bibr">37</xref></sup> LPS, and IFN&#x003b3; activate NF&#x003ba;B signaling. We did not test this hypothesis due to
high cell mortality upon NF&#x003ba;B inhibition.</p><p>In our experiments, the induction of TDO was specific for THP-1 and U937 cell lines
and could not be observed in other tumor-derived myeloid cell lines. In addition, it
contrasted with the lack of TDO expression in freshly isolated monocytes. In line
with this last observation, we described recently the expression profile of TDO in
solid tumors and showed that TDO is mostly expressed by tumor-associated pericytes
or vascular smooth muscle cells and, in some rare cases, in tumor cells surrounding
TDO-positive vessels.<sup><xref rid="bibr23-1178646919891736" ref-type="bibr">23</xref></sup> We did not observe TDO expression in tumor-associated macrophages. Therefore,
the induction of TDO seems to be restricted to tumoral monocytic cell lines. Other
human tumor lines are known to express TDO, including glioblastoma lines and lines
of colorectal, head and neck, and lung and gall-bladder carcinomas.<sup><xref rid="bibr18-1178646919891736" ref-type="bibr">18</xref></sup> Expression of TDO in mouse tumor cells allows them to resist immune
rejection.<sup><xref rid="bibr8-1178646919891736" ref-type="bibr">8</xref>,<xref rid="bibr18-1178646919891736" ref-type="bibr">18</xref></sup> It remains to be determined whether TDO expression in
differentiated THP-1 and U937 cells also provides them the ability to resist immune
attack.</p><p>Given the widespread use of THP-1 and U937 cells, our report of TDO induction in
these lines by PMA or LPS and IFN&#x003b3; might help interpreting the results of
experiments performed with these lines. In addition, a mechanistic study of TDO
induction in these lines could help characterizing the regulation of TDO expression
in normal and pathological contexts.</p></sec><sec sec-type="supplementary-material" id="section18-1178646919891736" specific-use="figshare"><title>Supplemental Material</title><supplementary-material content-type="local-data" id="suppl1-1178646919891736"><caption><title>Supplementary_Figures_cx1 &#x02013; Supplemental material for Induction of
tryptophan 2,3-dioxygenase expression in human monocytic leukemia/lymphoma
cell lines THP-1 and U937</title></caption><media xlink:href="Supplementary_Figures_cx1.pdf"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, Supplementary_Figures_cx1 for Induction of tryptophan
2,3-dioxygenase expression in human monocytic leukemia/lymphoma cell lines THP-1
and U937 by Delia Hoffmann, Luc Pilotte, Vincent Stroobant and Benoit J Van den
Eynde in International Journal of Tryptophan Research</p></supplementary-material></sec></body><back><ack><p>The authors thank iTeos Therapeutics for providing TDO-specific antibodies; Rui
Cheng, Violette Ferrari, and Tereza Dvorakova for their experimental help; the group
from Prof. Pierre Coulie for sharing with them their <italic>IL-1&#x003b2;</italic> RT-qPCR;
Nicolas Dauguet for his help with flow cytometry; and Auriane Sibille for editorial
assistance.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold>The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p></fn><fn fn-type="COI-statement"><p><bold>Declaration of conflicting interests:</bold>Beno&#x000ee;t Van den Eynde is the co-founder of, has ownership interest in, and is an
SAB member of iTeos Therapeutics.</p></fn><fn fn-type="con"><p><bold>Author Contributions:</bold> Conception and design: DH, LP and BJVdE</p><p>Methodology:DH, LP and BJVdE</p><p>Acquisition of data: DH, VS</p><p>Writing: DH and BJVdE</p><p>Study supervision: BJVdE</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Benoit J Van den Eynde <inline-graphic xlink:href="10.1177_1178646919891736-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-4995-3270">https://orcid.org/0000-0002-4995-3270</ext-link></p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1178646919891736"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>McKay</surname><given-names>D</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name><name><surname>Lewis</surname><given-names>CE.</given-names></name></person-group>
<article-title>Diverse functions of macrophages in different tumor
microenvironments</article-title>. <source>Cancer Res</source>.
<year>2018</year>;<volume>78</volume>:<fpage>5492</fpage>-<lpage>5503</lpage>.<pub-id pub-id-type="pmid">30206177</pub-id></mixed-citation></ref><ref id="bibr2-1178646919891736"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>CE.</given-names></name></person-group>
<article-title>Plasticity of macrophage function during tumor progression:
regulation by distinct molecular mechanisms</article-title>. <source>J
Immunol</source>.
<year>2008</year>;<volume>180</volume>:<fpage>2011</fpage>-<lpage>2017</lpage>.<pub-id pub-id-type="pmid">18250403</pub-id></mixed-citation></ref><ref id="bibr3-1178646919891736"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Mantovani</surname><given-names>A.</given-names></name></person-group>
<article-title>Macrophage plasticity and interaction with lymphocyte subsets:
cancer as a paradigm</article-title>. <source>Nat Immunol</source>.
<year>2010</year>;<volume>11</volume>:<fpage>889</fpage>-<lpage>896</lpage>.<pub-id pub-id-type="pmid">20856220</pub-id></mixed-citation></ref><ref id="bibr4-1178646919891736"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>PC</given-names></name><name><surname>Quiceno</surname><given-names>DG</given-names></name><name><surname>Ochoa</surname><given-names>AC.</given-names></name></person-group>
<article-title>L-arginine availability regulates T-lymphocyte cell-cycle
progression</article-title>. <source>Blood</source>.
<year>2007</year>;<volume>109</volume>:<fpage>1568</fpage>-<lpage>1573</lpage>.<pub-id pub-id-type="pmid">17023580</pub-id></mixed-citation></ref><ref id="bibr5-1178646919891736"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bronte</surname><given-names>V</given-names></name><name><surname>Zanovello</surname><given-names>P.</given-names></name></person-group>
<article-title>Regulation of immune responses by L-arginine
metabolism</article-title>. <source>Nat Rev Immunol</source>.
<year>2005</year>;<volume>5</volume>:<fpage>641</fpage>-<lpage>654</lpage>.<pub-id pub-id-type="pmid">16056256</pub-id></mixed-citation></ref><ref id="bibr6-1178646919891736"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mezrich</surname><given-names>JD</given-names></name><name><surname>Fechner</surname><given-names>JH</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Johnson</surname><given-names>BP</given-names></name><name><surname>Burlingham</surname><given-names>WJ</given-names></name><name><surname>Bradfield</surname><given-names>CA.</given-names></name></person-group>
<article-title>An interaction between kynurenine and the aryl hydrocarbon
receptor can generate regulatory T cells</article-title>. <source>J
Immunol</source>.
<year>2010</year>;<volume>185</volume>:<fpage>3190</fpage>-<lpage>3198</lpage>.<pub-id pub-id-type="pmid">20720200</pub-id></mixed-citation></ref><ref id="bibr7-1178646919891736"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terness</surname><given-names>P</given-names></name><name><surname>Bauer</surname><given-names>TM</given-names></name><name><surname>Rose</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Inhibition of allogeneic T
cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic
cells: mediation of suppression by tryptophan metabolites</article-title>.
<source>J Exp Med</source>.
<year>2002</year>;<volume>196</volume>:<fpage>447</fpage>-<lpage>457</lpage>.<pub-id pub-id-type="pmid">12186837</pub-id></mixed-citation></ref><ref id="bibr8-1178646919891736"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Opitz</surname><given-names>CA</given-names></name><name><surname>Litzenburger</surname><given-names>UM</given-names></name><name><surname>Sahm</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>
<article-title>An endogenous
tumour-promoting ligand of the human aryl hydrocarbon
receptor</article-title>. <source>Nature</source>.
<year>2011</year>;<volume>478</volume>:<fpage>197</fpage>-<lpage>203</lpage>.<pub-id pub-id-type="pmid">21976023</pub-id></mixed-citation></ref><ref id="bibr9-1178646919891736"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Munn</surname><given-names>DH</given-names></name><name><surname>Sharma</surname><given-names>MD</given-names></name><name><surname>Baban</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>GCN2 kinase in T cells
mediates proliferative arrest and anergy induction in response to
indoleamine 2,3-dioxygenase</article-title>. <source>Immunity</source>.
<year>2005</year>;<volume>22</volume>:<fpage>633</fpage>-<lpage>642</lpage>.<pub-id pub-id-type="pmid">15894280</pub-id></mixed-citation></ref><ref id="bibr10-1178646919891736"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Munn</surname><given-names>DH</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Attwood</surname><given-names>JT</given-names></name></person-group>, <etal>et al</etal>
<article-title>Prevention of allogeneic
fetal rejection by tryptophan catabolism</article-title>.
<source>Science</source>.
<year>1998</year>;<volume>281</volume>:<fpage>1191</fpage>-<lpage>1193</lpage>.<pub-id pub-id-type="pmid">9712583</pub-id></mixed-citation></ref><ref id="bibr11-1178646919891736"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dai</surname><given-names>W</given-names></name><name><surname>Gupta</surname><given-names>SL.</given-names></name></person-group>
<article-title>Regulation of indoleamine 2,3-dioxygenase gene expression in
human fibroblasts by interferon-gamma</article-title>. <source>J Biol
Chem</source>.
<year>1990</year>;<volume>265</volume>:<fpage>19871</fpage>-<lpage>19877</lpage>.<pub-id pub-id-type="pmid">2174056</pub-id></mixed-citation></ref><ref id="bibr12-1178646919891736"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chon</surname><given-names>SY</given-names></name><name><surname>Hassanain</surname><given-names>HH</given-names></name><name><surname>Pine</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>SL.</given-names></name></person-group>
<article-title>Involvement of two regulatory elements in
interferon-gamma-regulated expression of human indoleamine 2,3-dioxygenase
gene</article-title>. <source>J Interferon Cytokine Res</source>.
<year>1995</year>;<volume>15</volume>:<fpage>517</fpage>-<lpage>526</lpage>.<pub-id pub-id-type="pmid">7553221</pub-id></mixed-citation></ref><ref id="bibr13-1178646919891736"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uyttenhove</surname><given-names>C</given-names></name><name><surname>Pilotte</surname><given-names>L</given-names></name><name><surname>Theate</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal>
<article-title>Evidence for a tumoral
immune resistance mechanism based on tryptophan degradation by indoleamine
2,3-dioxygenase</article-title>. <source>Nat Med</source>.
<year>2003</year>;<volume>9</volume>:<fpage>1269</fpage>-<lpage>1274</lpage>.<pub-id pub-id-type="pmid">14502282</pub-id></mixed-citation></ref><ref id="bibr14-1178646919891736"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Theate</surname><given-names>I</given-names></name><name><surname>van Baren</surname><given-names>N</given-names></name><name><surname>Pilotte</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Extensive profiling of the
expression of the indoleamine 2,3-dioxygenase 1 protein in normal and
tumoral human tissues</article-title>. <source>Cancer Immunol Res</source>.
<year>2015</year>;<volume>3</volume>:<fpage>161</fpage>-<lpage>172</lpage>.<pub-id pub-id-type="pmid">25271151</pub-id></mixed-citation></ref><ref id="bibr15-1178646919891736"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spranger</surname><given-names>S</given-names></name><name><surname>Spaapen</surname><given-names>RM</given-names></name><name><surname>Zha</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Up-regulation of PD-L1, IDO,
and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T
cells</article-title>. <source>Sci Transl Med</source>.
<year>2013</year>;<volume>5</volume>:200ra116.</mixed-citation></ref><ref id="bibr16-1178646919891736"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hennequart</surname><given-names>M</given-names></name><name><surname>Pilotte</surname><given-names>L</given-names></name><name><surname>Cane</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Constitutive IDO1 expression
in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune
resistance</article-title>. <source>Cancer Immunol Res</source>.
<year>2017</year>;<volume>5</volume>:<fpage>695</fpage>-<lpage>709</lpage>.<pub-id pub-id-type="pmid">28765120</pub-id></mixed-citation></ref><ref id="bibr17-1178646919891736"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brochez</surname><given-names>L</given-names></name><name><surname>Chevolet</surname><given-names>I</given-names></name><name><surname>Kruse</surname><given-names>V.</given-names></name></person-group>
<article-title>The rationale of indoleamine 2,3-dioxygenase inhibition for
cancer therapy</article-title>. <source>Eur J Cancer</source>.
<year>2017</year>;<volume>76</volume>:<fpage>167</fpage>-<lpage>182</lpage>.<pub-id pub-id-type="pmid">28324751</pub-id></mixed-citation></ref><ref id="bibr18-1178646919891736"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pilotte</surname><given-names>L</given-names></name><name><surname>Larrieu</surname><given-names>P</given-names></name><name><surname>Stroobant</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>
<article-title>Reversal of tumoral immune
resistance by inhibition of tryptophan 2,3-dioxygenase</article-title>.
<source>Proc Natl Acad Sci U S A</source>.
<year>2012</year>;<volume>109</volume>:<fpage>2497</fpage>-<lpage>2502</lpage>.<pub-id pub-id-type="pmid">22308364</pub-id></mixed-citation></ref><ref id="bibr19-1178646919891736"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Baren</surname><given-names>N</given-names></name><name><surname>Van den Eynde</surname><given-names>BJ</given-names></name></person-group>
<article-title>Tryptophan-degrading enzymes in tumoral immune
resistance</article-title>. <source>Front Immunol</source>.
<year>2015</year>;<volume>6</volume>:<fpage>34</fpage>.<pub-id pub-id-type="pmid">25691885</pub-id></mixed-citation></ref><ref id="bibr20-1178646919891736"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanai</surname><given-names>M</given-names></name><name><surname>Funakoshi</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Tryptophan 2,3-dioxygenase
is a key modulator of physiological neurogenesis and anxiety-related
behavior in mice</article-title>. <source>Mol Brain</source>.
<year>2009</year>;<volume>2</volume>:<fpage>8</fpage>.<pub-id pub-id-type="pmid">19323847</pub-id></mixed-citation></ref><ref id="bibr21-1178646919891736"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tatsumi</surname><given-names>K</given-names></name><name><surname>Higuchi</surname><given-names>T</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Induction of tryptophan
2,3-dioxygenase in the mouse endometrium during
implantation</article-title>. <source>Biochem Biophys Res Commun</source>.
<year>2000</year>;<volume>274</volume>:<fpage>166</fpage>-<lpage>170</lpage>.<pub-id pub-id-type="pmid">10903913</pub-id></mixed-citation></ref><ref id="bibr22-1178646919891736"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kohro</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>A comparison of differences
in the gene expression profiles of phorbol 12-myristate 13-acetate
differentiated THP-1 cells and human monocyte-derived
macrophage</article-title>. <source>J Atheroscler Thromb</source>.
<year>2004</year>;<volume>11</volume>:<fpage>88</fpage>-<lpage>97</lpage>.<pub-id pub-id-type="pmid">15153668</pub-id></mixed-citation></ref><ref id="bibr23-1178646919891736"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>D</given-names></name><name><surname>Dvorakova</surname><given-names>T</given-names></name><name><surname>Stroobant</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>
<article-title>Tryptophan 2,3-dioxygenase
expression identified in human hepatocellular carcinoma cells and in
intratumoral pericytes of most cancers</article-title>. <source>Cancer
Immunol Res</source>. <year>2019</year>; <month>12</month>
<day>5</day> [Epub ahead of print].
doi:10.1158/2326-6066.CIR-19-0040.</mixed-citation></ref><ref id="bibr24-1178646919891736"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daigneault</surname><given-names>M</given-names></name><name><surname>Preston</surname><given-names>JA</given-names></name><name><surname>Marriott</surname><given-names>HM</given-names></name><name><surname>Whyte</surname><given-names>MK</given-names></name><name><surname>Dockrell</surname><given-names>DH.</given-names></name></person-group>
<article-title>The identification of markers of macrophage differentiation in
PMA-stimulated THP-1 cells and monocyte-derived macrophages</article-title>.
<source>PLoS ONE</source>.
<year>2010</year>;<volume>5</volume>:<fpage>e8668</fpage>.<pub-id pub-id-type="pmid">20084270</pub-id></mixed-citation></ref><ref id="bibr25-1178646919891736"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>RF</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>JT</given-names></name><name><surname>Yang</surname><given-names>KD.</given-names></name></person-group>
<article-title>Induction of IFN alpha or IL-12 depends on differentiation of
THP-1 cells in dengue infections without and with antibody
enhancement</article-title>. <source>BMC Infect Dis</source>.
<year>2012</year>;<volume>12</volume>:<fpage>340</fpage>.<pub-id pub-id-type="pmid">23216989</pub-id></mixed-citation></ref><ref id="bibr26-1178646919891736"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Serrano</surname><given-names>A</given-names></name><name><surname>Abril</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>
<article-title>Differential effect on U937
cell differentiation by targeting transcriptional factors implicated in
tissue- or stage-specific induced integrin expression</article-title>.
<source>Exp Hematol</source>.
<year>1999</year>;<volume>27</volume>:<fpage>353</fpage>-<lpage>364</lpage>.<pub-id pub-id-type="pmid">10029175</pub-id></mixed-citation></ref><ref id="bibr27-1178646919891736"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Alpert</surname><given-names>E.</given-names></name></person-group>
<article-title>Downregulation of phorbol 12-myristate 13-acetate-induced tumor
necrosis factor-alpha and interleukin-1 beta production and gene expression
in human monocytic cells by human alpha-fetoprotein</article-title>.
<source>Hepatology</source>.
<year>1995</year>;<volume>22</volume>:<fpage>921</fpage>-<lpage>928</lpage>.<pub-id pub-id-type="pmid">7544757</pub-id></mixed-citation></ref><ref id="bibr28-1178646919891736"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>YL</given-names></name><name><surname>Liu</surname><given-names>WW</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>
<article-title>Phorbol ester (PMA)-treated
U937 cells cultured on type I collagen-coated dish express a lower
production of pro-inflammatory cytokines through lowered ROS levels in
parallel with cell aggregate formation</article-title>. <source>Int
Immunopharmacol</source>.
<year>2018</year>;<volume>55</volume>:<fpage>158</fpage>-<lpage>164</lpage>.<pub-id pub-id-type="pmid">29253822</pub-id></mixed-citation></ref><ref id="bibr29-1178646919891736"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aldo</surname><given-names>PB</given-names></name><name><surname>Craveiro</surname><given-names>V</given-names></name><name><surname>Guller</surname><given-names>S</given-names></name><name><surname>Mor</surname><given-names>G.</given-names></name></person-group>
<article-title>Effect of culture conditions on the phenotype of THP-1 monocyte
cell line</article-title>. <source>Am J Reprod Immunol</source>.
<year>2013</year>;<volume>70</volume>:<fpage>80</fpage>-<lpage>86</lpage>.<pub-id pub-id-type="pmid">23621670</pub-id></mixed-citation></ref><ref id="bibr30-1178646919891736"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Danesch</surname><given-names>U</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Renkawitz</surname><given-names>R</given-names></name><name><surname>Schutz</surname><given-names>G.</given-names></name></person-group>
<article-title>Transcriptional regulation of the tryptophan oxygenase gene in
rat liver by glucocorticoids</article-title>. <source>J Biol Chem</source>.
<year>1983</year>;<volume>258</volume>:<fpage>4750</fpage>-<lpage>4753</lpage>.<pub-id pub-id-type="pmid">6187742</pub-id></mixed-citation></ref><ref id="bibr31-1178646919891736"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kheolamai</surname><given-names>P</given-names></name><name><surname>Dickson</surname><given-names>AJ.</given-names></name></person-group>
<article-title>Liver-enriched transcription factors are critical for the
expression of hepatocyte marker genes in mES-derived hepatocyte-lineage
cells</article-title>. <source>BMC Mol Biol</source>.
<year>2009</year>;<volume>10</volume>:<fpage>35</fpage>.<pub-id pub-id-type="pmid">19389256</pub-id></mixed-citation></ref><ref id="bibr32-1178646919891736"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>DD</given-names></name><name><surname>Gao</surname><given-names>YJ</given-names></name><name><surname>Tian</surname><given-names>XC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Differential expression and
regulation of Tdo2 during mouse decidualization</article-title>. <source>J
Endocrinol</source>.
<year>2014</year>;<volume>220</volume>:<fpage>73</fpage>-<lpage>83</lpage>.<pub-id pub-id-type="pmid">24190896</pub-id></mixed-citation></ref><ref id="bibr33-1178646919891736"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis-Ballester</surname><given-names>A</given-names></name><name><surname>Forouhar</surname><given-names>F</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Molecular basis for
catalysis and substrate-mediated cellular stabilization of human tryptophan
2,3-dioxygenase</article-title>. <source>Sci Rep</source>.
<year>2016</year>;<volume>6</volume>:<fpage>35169</fpage>.<pub-id pub-id-type="pmid">27762317</pub-id></mixed-citation></ref><ref id="bibr34-1178646919891736"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akeson</surname><given-names>AL</given-names></name><name><surname>Schroeder</surname><given-names>K</given-names></name><name><surname>Woods</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>CJ</given-names></name><name><surname>Jones</surname><given-names>WD.</given-names></name></person-group>
<article-title>Suppression of interleukin-1 beta and LDL scavenger receptor
expression in macrophages by a selective protein kinase C
inhibitor</article-title>. <source>J Lipid Res</source>.
<year>1991</year>;<volume>32</volume>:<fpage>1699</fpage>-<lpage>1707</lpage>.<pub-id pub-id-type="pmid">1797949</pub-id></mixed-citation></ref><ref id="bibr35-1178646919891736"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwende</surname><given-names>H</given-names></name><name><surname>Fitzke</surname><given-names>E</given-names></name><name><surname>Ambs</surname><given-names>P</given-names></name><name><surname>Dieter</surname><given-names>P.</given-names></name></person-group>
<article-title>Differences in the state of differentiation of THP-1 cells
induced by phorbol ester and 1,25-dihydroxyvitamin D3</article-title>.
<source>J Leukoc Biol</source>.
<year>1996</year>;<volume>59</volume>:<fpage>555</fpage>-<lpage>561</lpage>.<pub-id pub-id-type="pmid">8613704</pub-id></mixed-citation></ref><ref id="bibr36-1178646919891736"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D&#x02019;Amato</surname><given-names>NC</given-names></name><name><surname>Rogers</surname><given-names>TJ</given-names></name><name><surname>Gordon</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal>
<article-title>A TDO2-AhR signaling axis
facilitates anoikis resistance and metastasis in triple-negative breast
cancer</article-title>. <source>Cancer Res</source>.
<year>2015</year>;<volume>75</volume>:<fpage>4651</fpage>-<lpage>4664</lpage>.<pub-id pub-id-type="pmid">26363006</pub-id></mixed-citation></ref><ref id="bibr37-1178646919891736"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peters</surname><given-names>RT</given-names></name><name><surname>Liao</surname><given-names>SM</given-names></name><name><surname>Maniatis</surname><given-names>T.</given-names></name></person-group>
<article-title>IKKepsilon is part of a novel PMA-inducible IkappaB kinase
complex</article-title>. <source>Mol Cell</source>.
<year>2000</year>;<volume>5</volume>:<fpage>513</fpage>-<lpage>522</lpage>.<pub-id pub-id-type="pmid">10882136</pub-id></mixed-citation></ref></ref-list></back></article>